Ownership or leasing arrangements that allow a physician to benefit financially from referring their patients for tests remains controversial. These self-referral practices have been shown to be associated with increased utilization in settings where diagnostic imaging offers low clinical utility ([@pkz030-B1]). Whether the impact of these financial arrangements on imaging utilization varies across settings with different clinical utility and imaging guideline recommendations is unknown.

To address this question, we conducted a cohort study using Surveillance, Epidemiology, and End Results Medicare data. We included beneficiaries aged 66 years and older with newly diagnosed diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to capture discrete clinical settings where the utility of staging positron emission tomography (PET) varies by histology ([@pkz030-B5],[@pkz030-B6]). During our study period of 2004--2014, PET was recognized in clinical guidelines as being "essential" for staging DLBCL, "useful in select cases" of FL, and "generally not useful" for CLL/SLL ([@pkz030-B7]). We hypothesized ownership would have the greatest impact on PET utilization in FL and CLL/SLL, where the utility of PET is comparable to standard computer tomography imaging ([@pkz030-B7]).

Our study cohort included Medicare beneficiaries initiating first-line immunochemotherapy in the community setting. Beneficiaries were assigned to their treating oncologist using Healthcare Common Procedure Coding System codes that identified immunochemotherapy in Medicare claims ([@pkz030-B10]). Our main explanatory variable was whether a beneficiary's treating oncologist was listed as the billing provider on at least one PET claim, providing evidence of ownership or self-referral ([@pkz030-B1],[@pkz030-B2],[@pkz030-B4]). To accommodate changes in ownership or leasing arrangements, we evaluated Medicare PET claims within a 12-month look-back period from each treatment initiation to categorize active ownership status. Our primary outcome was a claim for PET or combined PET/computed tomography imaging within 60 days prior to first-line treatment. We evaluated pretreatment staging rather than initial staging at diagnosis because our study included histologies (FL and CLL/SLL) where patients can be observed for years prior to requiring lymphoma-directed therapy ([@pkz030-B7]).

In addition to descriptive statistics and bivariate analysis, we used linear probability models to estimate differences in receipt of PET by ownership status for our three non-Hodgkin lymphoma (NHL) subtypes. Our multivariable models included year of treatment, patient sociodemographics, Elixhauser comorbidity index, disability status ([@pkz030-B11]), and lymphoma stage ([@pkz030-B12]). We used χ^2^ to perform pairwise comparison of our linear probability estimates across the three models ([@pkz030-B13]). Two-sided statistical tests were completed using SAS version 9.4 (SAS Institute Inc., Cary, NC) with alpha = .05.

We identified 9879 Medicare beneficiaries diagnosed with DLBCL (n = 4917), FL (n = 2433), or CLL/SLL (n = 2529) initiating first-line therapy through 2014. The median age was 75 years (interquartile range = 71--81 years), and 50.3% were male ([Table 1](#pkz030-T1){ref-type="table"}). A total of 2014 oncologists were linked to our beneficiaries, with 178 (8.8%) listed as billing providers on at least one PET claim during our study period. In total, 735 of 9879 (7.4%) beneficiaries initiated therapy with active PET owners. These beneficiaries were more likely to receive a staging PET regardless of lymphoma subtype compared to those treated by non-owners (DLBCL: 72.8% vs 65.6%, *P* = .005; FL: 71.3% vs 53.2%, *P* \< .001; CLL/SLL: 29.4% vs 14.8%, *P* \< .001) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online).

###### 

Patient characteristics[\*](#tblfn1){ref-type="table-fn"}

  Characteristic                                                Overall       Treated by non-PET owning oncologist   Treated by PET owning oncologist   *P*
  ------------------------------------------------------------- ------------- -------------------------------------- ---------------------------------- --------
  Entire cohort                                                 9879          9144 (92.6)                            735 (7.4)                          ---
  Histology                                                                                                                                             .37
   CLL/SLL                                                      2529 (25.6)   2325 (25.4)                            204 (27.8)                         ---
   DLBCL                                                        4917 (49.8)   4560 (49.9)                            357 (48.6)                         ---
   FL                                                           2433 (24.6)   2259 (24.7)                            174 (23.7)                         ---
  Age group, y                                                                                                                                          .56
   66--69                                                       1869 (18.9)   1715 (18.8)                            154 (21.0)                         ---
   70--74                                                       2558 (25.9)   2376 (26.0)                            182 (24.8)                         ---
   75--79                                                       2463 (24.9)   2279 (24.9)                            184 (25.0)                         ---
   80--84                                                       1885 (19.1)   1744 (19.1)                            141 (19.2)                         ---
   ≥85                                                          1104 (11.2)   1030 (11.3)                            74 (10.1)                          ---
  Female sex                                                    4912 (49.7)   4525 (49.5)                            387 (52.7)                         .10
  Race                                                                                                                                                  \<.001
   Non-Hispanic white                                           8633 (87.4)   8015 (87.7)                            618 (84.1)                         ---
   Non-Hispanic black                                           300 (3.0)     282 (3.1)                              18 (2.5)                           ---
   Non-Hispanic other                                           432 (4.4)     397 (4.3)                              35 (4.8)                           ---
   Hispanic                                                     514 (5.2)     450 (4.9)                              64 (8.7)                           ---
  Married                                                       5700 (57.7)   5290 (57.9)                            410 (55.8)                         .27
  Year of treatment                                                                                                                                     \<.001
   2004--2005                                                   1703 (17.2)   1639 (17.9)                            64 (8.7)                           ---
   2006--2007                                                   2094 (21.2)   1917 (21.0)                            177 (24.1)                         ---
   2008--2009                                                   2239 (22.7)   2050 (22.4)                            189 (25.7)                         ---
   2010--2011                                                   1951 (19.8)   1772 (19.4)                            179 (24.4)                         ---
   2012--2014                                                   1892 (19.2)   1766 (19.3)                            126 (17.1)                         ---
  Geographic region                                                                                                                                     \<.001
   Midwest                                                      1452 (14.7)   1419 (15.5)                            33 (4.5)                           ---
   Northeast                                                    1876 (19.0)   1836 (20.1)                            40 (5.4)                           ---
   South                                                        2410 (24.4)   2229 (24.4)                            181 (24.6)                         ---
   West                                                         4141 (41.9)   3660 (40.0)                            481 (65.4)                         ---
  HS education (% adults ≥25 in zip code beyond HS education)                                                                                           \<.001
   ≥70                                                          2113 (21.4)   1895 (20.7)                            218 (29.7)                         ---
   60 to \<70                                                   1626 (16.5)   1534 (16.8)                            92 (12.5)                          ---
   50 to \<60                                                   2361 (23.9)   2227 (24.4)                            134 (18.2)                         ---
   40 to \<50                                                   1741 (17.6)   1627 (17.8)                            114 (15.5)                         ---
   \< 40                                                        2038 (20.6)   1861 (20.4)                            177 (24.1)                         ---
  Metro residency                                               8209 (83.1)   7629 (83.4)                            580 (78.9)                         .002
  Medicaid dual coverage                                        909 (9.2)     808 (8.8)                              101 (13.7)                         \<.001
  Elixhauser comorbidity index                                                                                                                          .58
   None                                                         3114 (31.5)   2871 (31.4)                            243 (33.1)                         ---
   1--2                                                         4122 (41.7)   3827 (41.9)                            295 (40.1)                         ---
   \>3                                                          2643 (26.8)   2446 (26.8)                            197 (26.8)                         ---
  Disabled                                                      735 (7.4)     664 (7.3)                              71 (9.7)                           .02
  Combined stage (Ann Arbor and CLL/SLL algorithm)                                                                                                      .03
   Early/Limited                                                3386 (34.3)   3135 (34.3)                            251 (34.2)                         ---
   Advanced                                                     4202 (42.5)   3916 (42.8)                            286 (38.9)                         ---
   Unknown                                                      2291 (23.2)   2093 (22.9)                            198 (26.9)                         ---

CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL = diffuse large B cell lymphoma; FL = follicular lymphoma; HS = high school; metro = metropolitan status; PET = positron emission tomography.

On adjusted analyses, the probability of receiving PET was 17% higher (95% confidence interval \[CI\] = 10% to 24%, *P* \< .001) for beneficiaries treated by physicians who were PET owners compared to non-owners in the setting of FL, where consensus guidelines on PET are equivocal, and 13% higher (95% CI = 6% to 20%, *P* \<.001) in the setting of CLL/SLL, where consensus guidelines recommend against PET. However, the difference between owners and non-owners was smaller (6%, 95% CI = 2% to 11%, *P* =.01) in the setting of DLBCL, where guidelines recommend use of PET. On pairwise testing, the association between PET ownership and staging differed between DLBCL and FL settings (z = 2.48, *P* = .04) ([Figure 1](#pkz030-F1){ref-type="fig"}).
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Prior research has also found imaging self-referral arrangements to be associated with greater utilization of diagnostic imaging ([@pkz030-B1]). However, this research focused on clinical settings where imaging offers low or marginal clinical utility, limiting the ability to address whether ownership is associated with appropriateness of scans. By evaluating three unique NHL settings with differing guideline recommendations, we set out to measure the association between ownership and appropriateness of staging PET. We found imaging ownership to be associated with higher rates of PET staging across NHL settings. However, the difference in PET staging between patients receiving care from PET owners vs non-owners was smallest in the setting where PET is of high clinical utility and recommended by guidelines.

Although our analysis offers novel findings, limitations exist. Appropriateness of imaging may depend on patient characteristics and symptoms not readily apparent in claims. This has limited the ability of prior work that focused on settings of lower back pain and headache to assess appropriateness of imaging ([@pkz030-B2],[@pkz030-B4]). Although staging for NHL is less influenced by patient characteristics outside of the known histologic diagnosis, appropriateness of PET staging could be influenced by whether patients are candidates for treatment with curative intent. However, these patient factors are likely to be relatively balanced among patients seeing PET owners and non-owners. Further, we restricted our DLBCL cohort to beneficiaries well enough to receive cytotoxic chemotherapy and adjusted for comorbidities and disability status in our multivariable models ([@pkz030-B11]) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, available online). Future studies outside of NHL and the Medicare population may be helpful to assess whether self-referral practices impact both appropriate and inappropriate testing.

In conclusion, Medicare beneficiaries newly diagnosed with NHL had greater utilization of PET staging when treated by oncologists with financial incentives tied to PET imaging. Ownership had the greatest impact on PET staging in the setting where clinical guidelines are equivocal (FL), with lesser effect in the setting where PET is recommended (DLBCL). Overall, policies limiting imaging self-referral practices may reduce utilization during cancer care, with greatest influence on settings where imaging is of equivocal or low clinical utility.
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